The subscription period in Elicera Therapeutics’ rights issue of units starts today

February 23, 2024

 

 

NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION IN WHOLE OR IN PART, DIRECTLY OR INDIRECTLY, IN THE UNITED STATES, AUSTRALIA, HONGKONG, JAPAN, CANADA, NEW ZEALAND, SWITZERLAND, SINGAPORE, SOUTH AFRICA, SOUTH KOREA OR ANY OTHER JURISDICTION WHERE SUCH RELEASE, PUBLICATION OR DISTRIBUTION WOULD BE UNLAWFUL OR WOULD REQUIRE REGISTRATION OR ANY OTHER MEASURES. PLEASE REFER TO IMPORTANT INFORMATION AT THE END OF THE PRESS RELEASE.

 

Today, February 23, 2024, the subscription period begins in Elicera Therapeutics AB’s (publ) (“Elicera” or the “Company”) rights issue of units consisting of shares and warrants, with preferential rights for existing shareholders (the "Rights Issue"), which the board of directors resolved on January 18, 2024 and that was approved at the extraordinary general meeting on February 20, 2024. The subscription period in the Rights Issue runs from and including February 23, 2024, up to and including March 8, 2024. However, note that some banks and nominees may have an earlier deadline for subscription in the Rights Issue. Shareholders should therefore check with their bank or nominee if they have an earlier deadline for subscription.

 

Timetable for the Rights Issue

  • February 21, 2024: Record date for obtaining unit rights. Shareholders who are registered in the share register kept by Euroclear Sweden AB on this day receive unit rights for participation in the Rights Issue
  • February 26 – March 5, 2024: Trading in unit rights (UR) on Nasdaq First North
  • February 23 – March 8, 2024: Subscription period for the Rights Issue
  • February 26 – week 12, 2024: Trading in BTU:s on Nasdaq First North
  • March 12, 2024: Estimated date for publication of issue results

 

Because of administrative issues the trade in the UR and BTU will initiate on Monday, February 26, 2024, instead of February 23 2024, as previously stated. Apart from that, the previously communicated timetable is unchanged.

 

For full terms and instructions, please refer to the EU growth prospectus for the rights issue published by the Company on February 21, 2024. The prospectus and summary folder are available on the company's website (www.elicera.com).

 

Subscription with preferential rights

The shareholders who, on the record date of February 21, 2024, were registered in the share register maintained by Euroclear Sweden AB ("Euroclear") and on behalf of the Company, directly registered shareholders, receive a pre-printed issue report with attached payment advice from Euroclear. In the event that a different number of unit rights than those stated in the pre-printed issue report are used for subscription, the special application form, which is available on the Company's website www.elicera.com, shall be used as a basis for subscription through cash payment.

 

Shareholders whose holdings of shares in the Company were nominee-registered with a bank or other nominee on the record date do not receive an issue report or a special application form from Euroclear. Subscription and payment must then instead take place in accordance with instructions from the respective trustee.

 

Subscription without preferential rights

Notification of subscription without preferential rights by a nominee is made in accordance with instructions from the respective nominee. For subscription through an endowment insurance or an investment savings account, please contact your nominee. Application for subscription without preferential rights in other respects is done by electronic subscription with Bank-ID on Mangold's website emission.mangold.se.

 

 

For more information, please contact:

Jamal El-Mosleh, CEO at Elicera Therapeutics AB

Mail: Jamal.elmosleh@elicera.com

Phone: +46 (0) 703 31 90 51

Webb: www.elicera.com

 

 

Certified Advisor

Carnegie Investment Bank AB (publ)

 

The information was submitted for publication distributed through the contact person below at 08;06 CET on February 23, 2024.

 

 

Advisers

Mangold Fondkommission AB is the financial advisor to Elicera in connection with the Rights Issue. Advokatfirman Delphi i Stockholm AB is the legal advisor to the Company in connection with the Rights Issue.

 

About Elicera Therapeutics AB

Elicera Therapeutics AB (publ) has developed the patented gene technology platform iTANK that enables the arming of new and existing CAR T-cell therapies targeting aggressive and relapsing cancer forms. Elicera Therapeutics thereby addresses a well-defined and vast market. The company’s CAR T-cell therapies have shown a potent effect toward solid tumors which are recognized as particularly difficult to treat and constitute the majority of cancer cases. The company addresses a global multibillion market in cell therapy through its offering of non-exclusive licensing of the iTANK-platform to companies in the pharmaceutical industry. Elicera Therapeutics has four internal development projects in immune therapy that separately have the potential to generate substantial value through exclusive out-licensing agreements. The company’s share is traded on Nasdaq First North Growth Market.. For additional information, visit www.elicera.com.

 

Important information

This press release is not an offer to sell shares or a solicitation of an offer to acquire securities of the Company. The contents of this press release have been prepared by the Company and the Company is solely responsible for its contents. The information in this press release is for background purposes only and therefore does not claim to be complete. No one should, for whatever reason, rely on the information contained in this press release or on its accuracy or completeness. The offer to subscribe for or acquire securities referred to in this press release is made through the EU growth prospectus provided by the Company, which contains detailed information about the Company.

 

This press release constitutes an advertisement and not a prospectus for the purposes of Regulation (EU) 2017/1129 of the European Parliament and of the Council of 14 June 2017 on the prospectus to be published when securities are offered to the public or admitted to trading on a regulated market, and repealing Directive 2003/71/EC (together with the related delegated and implementing regulations, the "Prospectus Regulation"). Investors should not invest in the securities referred to in this press release without having taken into account the information contained in the aforementioned EU growth prospectus.

 

The securities referred to in this press release have not been and will not be registered under the U.S. Securities Act as amended (the "Securities Act") and thus cannot be offered or sold in the United States absent registration or pursuant to an exemption from the registration requirements of the Securities Act or the securities laws of the relevant state. The Company does not intend to register any offering in the United States or to make any offer of securities in the United States. This press release will not be distributed within, and should not be sent to, the United States. The securities described herein have also not been, and will not be, registered under the applicable securities laws of Australia, Belarus, Canada, Hong Kong, Japan, New Zealand, Russia, Switzerland, Singapore, South Africa, South Korea or in any other jurisdiction in which the distribution of this press release would be unlawful or require additional measures other than those required by Swedish law and may not, subject to certain exceptions, be offered or sell within or into, or for the benefit of, any person whose registered address is in or who is located or resident in,  Australia, Belarus, Canada, Hong Kong, Japan, New Zealand, Russia, Switzerland, Singapore, South Africa or South Korea. There will be no offering of the securities described herein in Australia, Belarus, Canada, Hong Kong, Japan, New Zealand, Russia, Switzerland, Singapore, South Africa or South Korea.

 

In the United Kingdom, this press release may only be distributed and is only directed at (i) persons who have professional experience in matters relating to investments falling within Article 19(5) of the Financial Services and Markets Act 2000 (Financial Promotion) Order 2005 (the "Financial Promotion Order" as amended), (ii) persons falling within Article 49 (2) (a) to (d) ("high net worth companies;  unincorporated associations etc.") of the Financial Promotion Order, (iii) persons that are outside the United Kingdom, or (iv) are persons to whom an invitation or incentive to engage in investment activities (within the meaning of Section 21 of the Financial Services and Markets Act 2000 (“FSMA”)) in connection with the issue or sale of securities (all such persons together being referred to as "relevant persons"). This press release is only directed at relevant persons and persons who are not relevant persons must not act on or rely on the information contained in this press release. Any investment or investment activity to which this communication relates is only possible for relevant persons and will only be pursued with relevant persons.

 

In all EEA Member States ("EEA"), other than Sweden, this communication is only addressed to and is only directed at qualified investors in the relevant Member State as defined in the Prospectus Regulation, i.e. only those investors to whom an offer may be made without an approved prospectus in the relevant EEA Member State.

 

Topics covered in this press release may contain forward-looking statements. Such statements are all statements that are not historical facts and contain expressions such as "intends", "expects", "may", "plans", "estimates", "calculates" and other similar expressions. The forward-looking statements in this press release are based on various assumptions, many of which are based on additional assumptions. Although the Company believes that these assumptions were reasonable when made, such forward-looking statements are subject to known and unknown risks, uncertainties, coincidences, and other important factors that are difficult or impossible to predict and that are beyond the Company's control. Such risks, uncertainties and important factors could cause actual results to differ materially from those expressed or implied in this communication by the forward-looking statements. The information, opinions and forward-looking statements contained in this release speak only as of the date of this press release and are subject to change without notice. The Company does not undertake any obligation to review, update, confirm or release publicly any adjusted view of the forward-looking statements in order to reflect such events or circumstances that arise in relation to the content of these communications.

 

 

Download attachment (pdf)
< Back to press releases